User login
Key clinical point: The efficacy of calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) galcanezumab “wore off” before the next injection but only in a small sub-population of patients with chronic migraine (CM).
Major finding: The efficacy of galcanezumab vs placebo wore off at a significantly higher rate in patients with CM (risk ratio [RR] 1.91; 95% CI 1.11-3.28); however, the wearing-off effects of galcanezumab and placebo were not significantly different in the overall cohort (RR 1.29; 95% CI 0.73-2.28).
Study details: The data come from a meta-analysis of four randomized controlled trials including 2409 patients with migraine.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Asawavichienjinda T et al. "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. Cephalalgia. 2023;43(4):3331024231161261 (Mar 16). Doi: 10.1177/03331024231161261
Key clinical point: The efficacy of calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) galcanezumab “wore off” before the next injection but only in a small sub-population of patients with chronic migraine (CM).
Major finding: The efficacy of galcanezumab vs placebo wore off at a significantly higher rate in patients with CM (risk ratio [RR] 1.91; 95% CI 1.11-3.28); however, the wearing-off effects of galcanezumab and placebo were not significantly different in the overall cohort (RR 1.29; 95% CI 0.73-2.28).
Study details: The data come from a meta-analysis of four randomized controlled trials including 2409 patients with migraine.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Asawavichienjinda T et al. "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. Cephalalgia. 2023;43(4):3331024231161261 (Mar 16). Doi: 10.1177/03331024231161261
Key clinical point: The efficacy of calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) galcanezumab “wore off” before the next injection but only in a small sub-population of patients with chronic migraine (CM).
Major finding: The efficacy of galcanezumab vs placebo wore off at a significantly higher rate in patients with CM (risk ratio [RR] 1.91; 95% CI 1.11-3.28); however, the wearing-off effects of galcanezumab and placebo were not significantly different in the overall cohort (RR 1.29; 95% CI 0.73-2.28).
Study details: The data come from a meta-analysis of four randomized controlled trials including 2409 patients with migraine.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Asawavichienjinda T et al. "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. Cephalalgia. 2023;43(4):3331024231161261 (Mar 16). Doi: 10.1177/03331024231161261